Whitehawk Therapeutics Stock Performance
| WHWK Stock | 2.99 0.00 0.00% |
On a scale of 0 to 100, Whitehawk Therapeutics holds a performance score of 11. The firm maintains a market beta of 0.79, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Whitehawk Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Whitehawk Therapeutics is expected to be smaller as well. Please check Whitehawk Therapeutics' treynor ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether Whitehawk Therapeutics' historical returns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Whitehawk Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain basic indicators, Whitehawk Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (5.32) | Five Day Return 0.35 | Year To Date Return 16.8 | Ten Year Return (96.83) | All Time Return (96.83) |
Last Split Factor 1:15 | Last Split Date 2021-08-27 |
1 | Will Whitehawk Therapeutics Inc. stock deliver stable dividends - 2025 Biggest Moves AI Driven Stock Reports - newser.com | 11/19/2025 |
2 | How Whitehawk Therapeutics Inc. stock trades after earnings - 2025 Risk Factors Safe Capital Growth Trade Ideas - Newser | 12/02/2025 |
3 | Acerus Pharmaceuticals and Whitehawk Therapeutics Head-To-Head Contrast | 12/09/2025 |
4 | Acquisition by Bryan Ball of 366532 shares of Whitehawk Therapeutics, at 1.7 subject to Rule 16b-3 | 12/22/2025 |
5 | Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 | 01/08/2026 |
6 | Acquisition by Dugan Margaret of 650000 shares of Whitehawk Therapeutics at 2.26 subject to Rule 16b-3 | 02/04/2026 |
| Begin Period Cash Flow | 63 M | |
| Total Cashflows From Investing Activities | 25.2 M | |
| Free Cash Flow | -61.2 M |
Whitehawk | Build AI portfolio with Whitehawk Stock |
Whitehawk Therapeutics Relative Risk vs. Return Landscape
If you would invest 209.00 in Whitehawk Therapeutics on November 19, 2025 and sell it today you would earn a total of 76.00 from holding Whitehawk Therapeutics or generate 36.36% return on investment over 90 days. Whitehawk Therapeutics is currently generating 0.6063% in daily expected returns and assumes 4.2725% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Whitehawk, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Whitehawk Therapeutics Target Price Odds to finish over Current Price
The tendency of Whitehawk Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.99 | 90 days | 2.99 | under 4 |
Based on a normal probability distribution, the odds of Whitehawk Therapeutics to move above the current price in 90 days from now is under 4 (This Whitehawk Therapeutics probability density function shows the probability of Whitehawk Stock to fall within a particular range of prices over 90 days) .
Whitehawk Therapeutics Price Density |
| Price |
Predictive Modules for Whitehawk Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Whitehawk Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Whitehawk Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Whitehawk Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Whitehawk Therapeutics is not an exception. The market had few large corrections towards the Whitehawk Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Whitehawk Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Whitehawk Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.43 | |
β | Beta against Dow Jones | 0.79 | |
σ | Overall volatility | 0.26 | |
Ir | Information ratio | 0.10 |
Whitehawk Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Whitehawk Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Whitehawk Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Whitehawk Therapeutics appears to be risky and price may revert if volatility continues | |
| Whitehawk Therapeutics was previously known as Aadi Bioscience and was traded on NASDAQ Exchange under the symbol AADI. | |
| The company reported the previous year's revenue of 25.98 M. Net Loss for the year was (63.69 M) with loss before overhead, payroll, taxes, and interest of (73.45 M). | |
| Whitehawk Therapeutics generates negative cash flow from operations | |
| Whitehawk Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 67.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Dugan Margaret of 650000 shares of Whitehawk Therapeutics at 2.26 subject to Rule 16b-3 |
Whitehawk Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Whitehawk Stock often depends not only on the future outlook of the current and potential Whitehawk Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Whitehawk Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 27 M | |
| Cash And Short Term Investments | 47.2 M |
Whitehawk Therapeutics Fundamentals Growth
Whitehawk Stock prices reflect investors' perceptions of the future prospects and financial health of Whitehawk Therapeutics, and Whitehawk Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Whitehawk Stock performance.
| Return On Equity | -0.14 | ||||
| Return On Asset | -0.54 | ||||
| Profit Margin | (1.09) % | ||||
| Operating Margin | (7.54) % | ||||
| Current Valuation | (28.28 M) | ||||
| Shares Outstanding | 47.13 M | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 9.34 X | ||||
| Revenue | 25.98 M | ||||
| Gross Profit | (73.45 M) | ||||
| EBITDA | (64.63 M) | ||||
| Net Income | (63.69 M) | ||||
| Total Debt | 833 K | ||||
| Book Value Per Share | 3.33 X | ||||
| Cash Flow From Operations | (59.55 M) | ||||
| Earnings Per Share | (0.64) X | ||||
| Market Capitalization | 134.32 M | ||||
| Total Asset | 70.32 M | ||||
| Retained Earnings | (332.65 M) | ||||
| Working Capital | 44.21 M | ||||
About Whitehawk Therapeutics Performance
By examining Whitehawk Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Whitehawk Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Whitehawk Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 32.28 | 26.98 | |
| Return On Tangible Assets | (1.04) | (1.09) | |
| Return On Capital Employed | (1.46) | (1.38) | |
| Return On Assets | (1.04) | (1.09) | |
| Return On Equity | (1.40) | (1.33) |
Things to note about Whitehawk Therapeutics performance evaluation
Checking the ongoing alerts about Whitehawk Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Whitehawk Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Whitehawk Therapeutics appears to be risky and price may revert if volatility continues | |
| Whitehawk Therapeutics was previously known as Aadi Bioscience and was traded on NASDAQ Exchange under the symbol AADI. | |
| The company reported the previous year's revenue of 25.98 M. Net Loss for the year was (63.69 M) with loss before overhead, payroll, taxes, and interest of (73.45 M). | |
| Whitehawk Therapeutics generates negative cash flow from operations | |
| Whitehawk Therapeutics has a poor financial position based on the latest SEC disclosures | |
| About 67.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Dugan Margaret of 650000 shares of Whitehawk Therapeutics at 2.26 subject to Rule 16b-3 |
- Analyzing Whitehawk Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Whitehawk Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Whitehawk Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Whitehawk Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Whitehawk Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Whitehawk Therapeutics' stock. These opinions can provide insight into Whitehawk Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Whitehawk Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. For more information on how to buy Whitehawk Stock please use our How to buy in Whitehawk Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Whitehawk Therapeutics. Anticipated expansion of Whitehawk directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Whitehawk Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.64) | Revenue Per Share | Quarterly Revenue Growth 0.335 | Return On Assets | Return On Equity |
Investors evaluate Whitehawk Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Whitehawk Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Whitehawk Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Whitehawk Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Whitehawk Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Whitehawk Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.